 "Merck")
The pharmaceutical company Merck says it has asked the European Medicines Agency to authorize its COVID-19 antiviral treatment, the first pill that has been shown to treat the disease.
In a statement on Monday, Merck said the EU drug regulator had started an expedited licensing process for molnupiravir. If given the green light, it would be the first treatment for COVID-19 that does not need to be administered through needles or intravenous infusions.
Earlier this month, Merck asked the U.S. Food and Drug Administration to okay molnupiravir, and a decision is expected within weeks.
The company reported this month that the pill cut hospitalizations and deaths by half among patients with early symptoms of COVID-19. The results were so strong that independent medical experts monitoring the trial recommended stopping it early.
An antiviral pill that people could take at home to reduce their symptoms and speed recovery could prove groundbreaking, easing the crushing caseload on hospitals and helping to curb outbreaks in poorer countries with weak health care systems.
It would also bolster a two-pronged approach to the pandemic: treatment, by way of medication, and prevention, primarily through vaccinations.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
